22539-55-5

Basic information

• Product Name: 8-chloro-5-nitro-quinoline
• Synonyms: 8-chloro-5-nitro-quinoline;AKOS BBR-004754;Nsc74384;5-Nitro-8-chloroquinoline;Quinoline, 8-chloro-5-nitro-
• CAS NO: 22539-55-5
• Molecular Formula: C₉H₅ClN₂O₂
• Molecular Weight: 208.6
• EINECS: -0
• Mol File: 22539-55-5.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 353.6 °C at 760 mmHg
• Flash Point: 167.6 °C
• Appearance: /
• Density: 1.484 g/cm³
• Vapor Pressure: 7.24E-05mmHg at 25°C
• Refractive Index: 1.688
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 8-chloro-5-nitro-quinoline(CAS DataBase Reference)
• NIST Chemistry Reference: 8-chloro-5-nitro-quinoline(22539-55-5)
• EPA Substance Registry System: 8-chloro-5-nitro-quinoline(22539-55-5)

Safety Data

• Hazardous Substances Data: 22539-55-5(Hazardous Substances Data)

Usage

General Description

8-chloro-5-nitro-quinoline is a synthetic compound that is part of the quinoline family. Quinolines are aromatic compounds with a nitrogen atom in its structure, often used in pharmaceutical applications. This particular compound possesses a chlorine atom at the 8th position and a nitro group at the 5th position of the basic quinoline structure, hence its name. It is commonly used in scientific research and can act as a precursor for the synthesis of other compounds. Chemically, it is recognized for its chemical stability and reactivity. However, like other synthetic chemicals, it should be handled properly as it may pose potential risks. The complete toxicological and safety profile of 8-chloro-5-nitro-quinoline is not well-defined and more investigation is warranted to fully understand its biological impacts.

InChI:InChI=1/C9H5ClN2O2/c10-7-3-4-8(12(13)14)6-2-1-5-11-9(6)7/h1-5H

Upstream product

• 6283-25-6 H₂NC₆H₃(Cl)NO₂ 
• 56-81-5 glycerol 
• 107-02-8 acrolein 
• 4008-48-4 nitroxoline 
• 68-12-2 N,N-dimethyl-formamide 
• 95-51-2 o-chloroaniline 
• 611-33-6 8-chloroquinoline 

Downstream Products

• 703-32-2 5,8-Dichlor-chinolin 
• 1602769-85-6 8-(4-methoxybenzylthio)-5-nitroquinoline 
• 1602769-90-3 8-(4-(4-methylpiperazin-1-yl)phenoxy)-5-nitroquinoline 
• 1602769-91-4 1-(4-(4-(5-nitroquinolin-8-yloxy)phenyl)piperazin-1-yl)ethanone 
• 855761-34-1 8-benzenesulfonyl-5-nitro-quinoline 
• 861038-22-4 8-benzenesulfonyl-[5]quinolylamine 
• 75793-58-7 8-chloroquinolin-5-amine 
• 855761-38-5 5-nitro-8-phenylsulfanyl-quinoline 
• 87236-39-3 5-Nitro-8-(4-phenyl-5-pyridin-4-yl-4H-[1,2,4]triazol-3-ylsulfanyl)-quinoline 
• 87236-38-2 MIND₄A 
• 102244-04-2 4-(5-Nitro-quinolin-8-ylsulfanyl)-quinazoline 

Relevant articles and documents

The fight against the influenza A virus H1N1: Synthesis, molecular modeling, and biological evaluation of benzofurazan derivatives as viral RNA polymerase inhibitors

The influenza RNA polymerase complex, which consists of the three subunits PA, PB1, and PB2, is a promising target for the development of new antiviral drugs. A large library of benzofurazan compounds was synthesized and assayed against influenza virus A/WSN/33 (H1N1). Most of the new derivatives were found to act by inhibiting the viral RNA polymerase complex through disruption of the complex formed between subunits PA and PB1. Docking studies were also performed to elucidate the binding mode of benzofurazans within the PB1 binding site in PA and to identify amino acids involved in their mechanism of action. The predicted binding pose is fully consistent with the biological data and lays the foundation for the rational development of more effective PA-PB1 inhibitors. In the fight against influenza virus A/WSN/33 (H1N1), the PA-PB1 protein-protein interaction is emerging as a new drug target. To identify small molecules able to inhibit the viral RNA polymerase complex, the benzofurazan scaffold was explored by synthesizing a large library of derivatives. Some compounds showed high anti-H1N1 activity and emerged as effective inhibitors of the PA-PB1 interaction, with IC50 values in the micromolar range. Copyright